Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma (NCT00602641)
An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide (MPT) Versus Melphalan, Prednisone and Lenalidomide (Revlimid(TM))(MPR) in Newly Diagnosed Multiple Myeloma Patients Who Are Not Candidates for High-Dose Therapy
🩺 Plain-English Summary (8th-Grade Level)
This randomized phase III trial studies melphalan and prednisone with thalidomide to see how well it works compared to melphalan and prednisone together with lenalidomide in treating patients with newly diagnosed multiple myeloma. Drugs used in chemotherapy, such as melphalan and prednisone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Thalidomide and lenalidomide may stop the growth of multiple myeloma by blocking blood flow to the cancer. It is not yet known whether melphalan and prednisone are more effective when given together with thalidomide or lenalidomide in treating multiple myeloma.
Who can join: Review the eligibility criteria below.
Location: Providence Hospital — Mobile, Alabama
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (391 Sites)
Showing the first 25 of 391 sites.
- Providence Hospital — Mobile, Alabama
- Mayo Clinic in Arizona — Scottsdale, Arizona
- Sparks Regional Medical Center — Fort Smith, Arkansas
- UC San Diego Moores Cancer Center — La Jolla, California
- Fremont - Rideout Cancer Center — Marysville, California
- Memorial Medical Center — Modesto, California
- University of California Davis Comprehensive Cancer Center — Sacramento, California
- UC San Diego Medical Center - Hillcrest — San Diego, California
- Kaiser Permanente-Rio San Diego — San Diego, California
- San Diego VA Medical Center — San Diego, California
- Gene Upshaw Memorial Tahoe Forest Cancer Center — Truckee, California
- The Medical Center of Aurora — Aurora, Colorado
- Boulder Community Foothills Hospital — Boulder, Colorado
- Penrose-Saint Francis Healthcare — Colorado Springs, Colorado
- AdventHealth Porter — Denver, Colorado
- Presbyterian - Saint Lukes Medical Center - Health One — Denver, Colorado
- Saint Joseph Hospital - Cancer Centers of Colorado — Denver, Colorado
- Rose Medical Center — Denver, Colorado
- Western States Cancer Research NCORP — Denver, Colorado
- Swedish Medical Center — Englewood, Colorado
- Poudre Valley Hospital — Fort Collins, Colorado
- Saint Mary's Hospital and Regional Medical Center — Grand Junction, Colorado
- Banner North Colorado Medical Center — Greeley, Colorado
- CommonSpirit Saint Anthony Hospital Cancer Center — Lakewood, Colorado
- Sky Ridge Medical Center — Lone Tree, Colorado
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Multiple Myeloma
- Ixazomib + Pomalidomide + Dexamethasone In MM — Boston, Massachusetts
- A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma — Birmingham, Alabama
- Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant — Tampa, Florida
- MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb — Beverly Hills, California
- A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma — Phoenix, Arizona
- A Study of Carfilzomib, Lenalidomide, Vorinostat, and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma — Hackensack, New Jersey
Explore by condition: All Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.